CureVac says its mRNA-based COVID-19 vaccine candidate, CVnCoV, remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature of +5°C (+41°F) and up to 24 hours as ready-to-use vaccine when stored at room temperature.
“Transport and storage of vaccines requiring ultra-low temperature setups to keep them stable, has been the topic of intense discussions and concerns in terms of feasibility, added costs and wastage,” said Dr Florian von der Mülbe, Chief Production Officer of CureVac.
“We are very encouraged by the emerging stability profile of our COVID-19 vaccine candidate compatible with standard fridge-temperature storage as well as a required room temperature application. This compatibility has the potential both to enable decentralised storage and to significantly facilitate large-scale vaccination efforts during the current pandemic.”
Storage of sample material, as well as analytical testing of CVnCoV was performed under standard conditions defined by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
Image credit: CDC
